Urenco Group
Long-term (multi-year to multi-decade) enrichment contracts with roughly 50 utility customers in about 20 countries; sells separative work units (SWU) and enriched uranium product from four centrifuge sites; adding HALEU for advanced reactors
Urenco has never had a funding round: it is a treaty-governed state-owned enterprise (UK 1/3, Netherlands 1/3, E.ON+RWE 1/3) that self-funds via retained earnings and rated bond issuance (Urenco Finance N.V.). The trail therefore uses the only real external valuation events that exist - the 2013-2016 government sale/IPO process press valuations - plus the current comps-based estimate. No primary equity has ever been priced by a market.
Earnings, margins, COGS & capex
FY2025 (calendar year, audited, released 12 March 2026): revenue EUR 2,096.2m (+11.7%), EBITDA EUR 804.2m (+10.4% vs EUR 728.1m, 38.4% margin), operating income EUR 431.3m (+50.7%), net income EUR 248.5m (+37.9% vs EUR 180.3m). Order book hit a record EUR 21.3bn (+14% vs EUR 18.7bn), extending into the 2040s, after EUR 14.7bn in 2023 - a third straight year of strong growth. Capex jumped 31% to EUR 615.8m as the 2.5m-SWU expansion program builds at Eunice (NM), Almelo, Gronau and Capenhurst; balance sheet remains net cash (EUR 844.5m). Note FY2023 (EUR 1,922.3m revenue, EUR 886.7m EBITDA) exceeded FY2024 on both lines - reported results are lumpy with delivery timing and provision movements, so the order book is a better growth signal than any single year.
Revenue trend
Margins
roughly flat (38.8% FY2024); FY2023 was higher at ~46% (EUR 886.7m EBITDA) on provision effects
up from 15.3% FY2024
up from 9.6% FY2024
COGS structure
Cost base is dominated by depreciation of centrifuge plant (centrifuges spin for decades; heavy D&A explains the EBITDA-to-operating-margin gap), electricity (centrifuge enrichment is far more power-efficient than legacy gaseous diffusion, but power is still a key input), feed uranium handling, and tails (depleted UF6) management/deconversion provisions - a large, long-dated decommissioning and tails liability sits on the balance sheet, unusual in scale versus most industrials.
Capex
EUR 615.8m FY2025 (+31% YoY), ~29% of revenue and rising. Current program: ~700,000 new SWU at Eunice, NM (three new cascades operational in 2025, completion targeted around 2027), Almelo expansion doubled to ~1.5m SWU (an additional 750,000 SWU on the original plan), Gronau construction proceeding, and the UK-government-backed HALEU line at Capenhurst (up to ~27 tU/year, production from ~2031). Total program delivers ~2.5m new SWU. June 2026: Urenco USA additionally announced a multi-billion-dollar new enrichment plant at Eunice adding 2.1m SWU (almost +50% US capacity; construction from 2029, first LEU 2032, full production 2036), privately funded with no federal award attached; site capacity grows to over 7m SWU within a decade.
Latest earnings
Not applicable - private company, no sell-side consensus
No numeric 2026 guidance disclosed; management points to the record order book, the 2.5m-SWU capacity program plus the new 2.1m-SWU US plant, and continued price momentum
- Order book
- EUR 21.3bn (+14% YoY), extends into the 2040s
- EBITDA
- EUR 804.2m, 38.4% margin
- Capex
- EUR 615.8m (+31%)
- Net cash
- EUR 844.5m
- SWU spot price
- $200/SWU at end-2025 (vs $193 end-2024)
Growth drivers
- Western utilities replacing Russian (Rosatom/TENEX) enrichment — the US Prohibiting Russian Uranium Imports Act (ban effective August 2024, DOE waiver authority expires 1 January 2028) and European de-risking push demand toward Urenco
- Record EUR 21.3bn order book (+14% YoY; EUR 14.7bn 2023, EUR 18.7bn 2024) contracted into the 2040s
- Higher realised SWU prices rolling through the contract book (SWU spot rose from roughly $56 in 2021 to $200 at end-2025)
- Life extensions and restarts of existing reactor fleets plus new large builds increasing enrichment demand
- HALEU for advanced reactors/SMRs (Capenhurst up to ~27 tU/yr line from ~2031; US HALEU at Eunice under evaluation) plus early advanced-reactor LEU offtake (first commercial enriched-uranium delivery to a US advanced-reactor developer, Aalo Atomics, contracted 2025)
- AI/data-center-driven nuclear power demand expanding the long-run SWU market
Bull & bear
Urenco is the single biggest structural winner from the West's divorce from Rosatom: an effective duopoly (with Orano) over Western enrichment, a record EUR 21.3bn order book contracted into the 2040s at rising prices, a net-cash balance sheet self-funding a multi-million-SWU expansion, and a first-mover HALEU position just as AI-driven nuclear demand inflects.
- SWU spot has roughly tripled since 2021 (about $56 to $200 at end-2025) and legacy contracts reprice upward for years - revenue grew 11.7% in FY2025 on price alone, before new capacity lands
- Order book +14% to EUR 21.3bn (about 10x annual revenue), after EUR 14.7bn in 2023 and EUR 18.7bn in 2024 - demand visibility into the 2040s that de-risks the capex program
- The expiry of US waivers on Russian LEU (1 January 2028) forces a large slice of historical Western supply to be replaced; Urenco is the largest qualified alternative and the only foreign enricher already operating a US plant
- Expansion economics are attractive: adding cascades to licensed, operating sites (Eunice, Almelo, Gronau) is the cheapest, fastest capacity in the industry - and the June 2026 US plant proceeds on private funding, no federal award needed
- HALEU and advanced-fuel optionality: Capenhurst's line (up to ~27 tU/yr from ~2031) is Western Europe's first commercial HALEU plant, Urenco already made the first commercial enriched-uranium delivery to a US advanced-reactor developer (Aalo), and SMR fuel demand (Oklo, TerraPower, X-energy class) is largely unserved outside DOE programs
- Net cash of EUR 844.5m plus EUR 804.2m EBITDA fund growth internally - no dilution, no distressed financing risk
A state-owned utility-supplier whose windfall is policy-made and can be policy-unmade: pricing depends on Russian exclusion holding, free cash flow is consumed by a four-site build program for most of a decade, subsidized competition (Centrus, GLE) is scaling into its best market, and governance under three governments makes it slow, unsaleable and un-investable in any direct sense.
- The entire price upcycle rests on geopolitics: any post-conflict normalization with Russia reopens roughly 40% of global enrichment capacity at the industry's lowest cost, and $200 SWU does not survive that
- FCF is thin-to-negative through the ramp: capex is ~29% of revenue and rising, on top of large tails/decommissioning liabilities - EBITDA less capex was only ~EUR 188m in FY2025
- EBITDA is still below FY2023's EUR 886.7m and FY2024 revenue actually fell - reported P&L momentum is lumpier than the narrative suggests
- Centrus's $900m DOE HALEU contract (July 2026, options taking it over $1bn, 12 tHM/yr initial build-out plus LEU capacity from ~2029) and broader US industrial policy are building a subsidized domestic competitor; GLE's laser route (Silex/Cameco) targets structurally lower cost by the 2030s
- New capacity across Urenco, Orano, Centrus and GLE could overshoot if reactor demand disappoints - enrichment has a history of decade-long gluts (SWU spot spent most of 2013-2021 below $60)
- For an investor there is no direct way in: no listing, no secondaries, and a Treaty of Almelo governance structure that has stalled past sale discussions - exposure is only available via proxies (CCJ, LEU, SLX.AX, CEG), each an imperfect tracker
What it is worth
EV/EBITDA comps plus order-book sanity check - illustrative only; Urenco is state-owned with no market print, no priced round, and no realistic near-term listing (the Treaty of Almelo structure requires tripartite government consent)
~$5-6B equity (6x EBITDA on Russian re-entry risk, capex overrun, and tails liabilities marked harder)
~$8-10B equity (8-10x FY2025 EBITDA plus net cash)
~$13-15B equity (12x+ EBITDA on order-book momentum, $200+ SWU sustained, HALEU optionality priced)
FY2025 EBITDA EUR 804.2m, net cash EUR 844.5m, order book EUR 21.3bn. Public proxies trade rich (Centrus LEU and Cameco CCJ carry premium multiples on the same de-Russification thesis), but Urenco's state ownership, tails/decommissioning liabilities and capex ramp argue for infrastructure-style multiples. Base 8-10x EV/EBITDA implies EV ~EUR 6.4-8.0bn, equity ~EUR 7.3-8.9bn (~$8-10B). The only external anchor is the stalled 2013-2016 sale process, where the whole company was press-valued at ~EUR 10bn (~$13B at the time) before the process died on tripartite-governance and security grounds. Direct investment is not possible; exposure is via proxies (LEU, CCJ, SLX.AX, CEG). Not financial advice.
SWOT
Strengths
- Largest SWU production capacity in the OECD — one of only two Western commercial enrichers at scale (with Orano)
- Record EUR 21.3bn contracted order book into the 2040s - multi-decade revenue visibility few companies possess
- Only enricher with plants on both sides of the Atlantic (UK, NL, Germany, US) - jurisdictional diversification peers lack
- Net-cash balance sheet (EUR 844.5m) funding the expansion largely internally - the June 2026 US plant is privately funded with no federal award (Capenhurst HALEU does carry a GBP 196m UK government award)
- Proven, proprietary centrifuge technology (via the ETC JV with Orano) with decades of operating record and extreme barriers to replication
Weaknesses
- State-owned tripartite structure under the Treaty of Almelo — governance is political, strategic decisions (sale, IPO, big capital moves) need three-government alignment
- Heavy and rising capex (~29% of revenue) compresses free cash flow for years
- Large long-dated tails/decommissioning liabilities on the balance sheet
- Reported results are lumpy (FY2024 revenue and EBITDA fell despite the structural upcycle) - delivery timing, not demand, drives any single year
- No equity currency and no access to public equity markets to fund growth
Opportunities
- Capture the large share of Western enrichment demand still met by Russia as the US waiver expiry (1 January 2028) and EU de-risking bite
- HALEU: first commercial Western European HALEU facility (Capenhurst, up to ~27 tU/yr from ~2031) plus potential US HALEU at Eunice for the SMR wave
- AI/data-center nuclear demand (restarts, uprates, SMRs) expanding the long-run SWU market beyond current forecasts
- Higher-priced recontracting: legacy contracts rolling onto $200/SWU spot-era pricing
- US expansion (2.1m SWU, almost +50% US capacity, announced June 2026) into the world's largest and most supply-short enrichment market
Threats
- Russian re-entry — if sanctions/waiver politics soften post-2027, TENEX's low-cost capacity could cap SWU prices
- Centrus Energy scaling US LEU+HALEU with a $900m DOE contract (signed 1 July 2026) - a subsidized domestic rival in Urenco's best market
- Laser enrichment (Global Laser Enrichment - Silex/Cameco) could eventually undercut centrifuge economics
- Demand risk if reactor construction slips or SMR deployment disappoints, stranding new capacity
- A nuclear incident anywhere in the world re-freezing public acceptance and demand
- Execution/inflation risk on a simultaneous four-site, multi-billion build program
Moats, dependencies & bottlenecks
Moats
Enrichment is the most proliferation-sensitive step of the fuel cycle; new entrants need international treaty cover, national licensing, and safeguards - effectively impossible for a private newcomer
until laser enrichment matures Decades of classified centrifuge R&D shared only with Orano via the Enrichment Technology Company JV; cannot be licensed or copied
EUR 21.3bn of long-term contracts; utilities qualify fuel suppliers over years and rarely switch
Jurisdictional diversification matters to utilities buying security of supply, not just SWU
Largest OECD SWU capacity, but Rosatom is cheaper and GLE laser enrichment could reset the cost curve in the 2030s
Dependencies
The price and volume upcycle is largely a function of Rosatom exclusion; reversal is the single biggest risk
NL, E.ON/RWE under Treaty of Almelo) Strategic moves need tripartite alignment; historical sale discussions stalled on it
supplier/technology Centrifuge manufacture shared with its main Western competitor
Kazatomprom, Orano, Honeywell/ConverDyn) Conversion is the tightest link in the Western fuel chain; enrichers need converted UF6 to run
Centrifuges are power-efficient but energy is still a core input
2.5m new SWU plus the 2.1m-SWU US plant must be absorbed; SMR/HALEU demand is still mostly pre-commercial
Advantages
- Effective Western duopoly position (with Orano) in a market structurally short ex-Russia supply
- Roughly 10x revenue in contracted order book - visibility almost no industrial company has
- Largely self-funded growth — net cash plus EUR 800m+ EBITDA versus peers needing government money (Centrus) or unproven tech (GLE)
- Incumbent licensed sites - brownfield expansion is faster and cheaper than any greenfield competitor
- First commercial Western European HALEU capacity in flight, plus the first commercial enriched-uranium delivery to a US advanced-reactor developer (Aalo)
Weaknesses
- No public equity, no currency for M&A, politically constrained ownership
- Free cash flow suppressed by the capex super-cycle for most of the decade
- Large legacy tails/decommissioning liabilities
- Earnings lumpiness obscures the underlying trend year to year
- Exposed to a single product (SWU) whose price is policy-driven
Bottlenecks
- Centrifuge cascade manufacturing and installation pace at ETC — capacity adds are measured in years per tranche
- Western conversion (UF6) capacity upstream — enrichment expansion outrunning conversion would idle new cascades
- Licensing and construction timelines for HALEU (Capenhurst production only from ~2031) and the new US plant (construction 2029, full production 2036)
- Skilled nuclear workforce across four simultaneous site expansions
- Tails deconversion and storage capacity as throughput rises
Top signals & trends
Top signals
Hard deadline forcing Western utilities to recontract with Urenco/Orano/Centrus
Third straight year of strong growth; watch the FY2026 print for continuation
Management conviction backed by contracts, not subsidies
Subsidized US competitor scaling at Piketon (12 tHM/yr HALEU initial build-out plus LEU capacity from ~2029); watch its deployment pace
bullish while >$150 · Any sustained rollover would signal supply catching up or Russian re-entry expectations
bearish long-term · Success would threaten the centrifuge cost curve in the 2030s
Periodically rumoured; the Treaty of Almelo makes it slow, but it is the only path to direct investability
Trends
strongly positive · Structural, multi-decade demand shift toward Western enrichers; the core thesis
Restarts, uprates, life extensions and new builds all add SWU demand
positive but slow · Real fuel demand mostly post-2030; Urenco is positioning early at Capenhurst and Eunice
Grows the market but subsidizes competitor Centrus
negative late-decade · Overshoot risk if demand slips; enrichment is glut-prone
negative in the 2030s if it works · GLE targets lower-cost SWU and tails re-enrichment
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Uranium mining and conversion (Port Hope) feeding Western enrichers
World's largest uranium miner; feed supply to Western fuel buyers
Sole US UF6 conversion capacity - critical upstream bottleneck for Urenco USA
French UF6 conversion (Philippe Coste plant) supplying European enrichment feed
50/50 Urenco-Orano JV that designs and manufactures the centrifuges themselves
Largest US nuclear fleet operator - archetypal Urenco LEU customer
Major US nuclear utility customer base for enrichment services
US nuclear utility; Urenco serves roughly 50 customers in about 20 countries
Europe's largest nuclear operator; European utility demand anchors the Almelo/Gronau expansion
Signed a 2025 contract for Urenco LEU - the first commercial enriched-uranium delivery to a US advanced-reactor company, fueling the Aalo-X
Advanced-reactor developer class needing HALEU - the emerging customer segment
Private SMR/advanced reactor developers; future HALEU demand pool
World's largest, lowest-cost enricher (roughly 40% of global capacity); excluded from Western markets by sanctions and the US import ban - the swing factor for SWU prices
The other Western centrifuge enricher (Georges Besse II); shares the ETC centrifuge JV with Urenco; expanding and planning a US plant (Oak Ridge, TN)
US-listed enricher restarting American centrifuge capacity at Piketon; $900m DOE HALEU contract signed July 2026; currently far smaller but heavily subsidized
Third-generation laser enrichment; pre-commercial, targeting the 2030s; potential cost-curve disruptor
Expanding Chinese enrichment capacity; serves domestic/aligned markets - context for global supply only, not a Western-market competitor